Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study-Reference-Cited by-同舟云学术

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

Published:2017-05-18 Issue:8 Volume:102 Page:1368-1377
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Rea Delphine,Henry Guylaine,Khaznadar Zena,Etienne Gabriel,Guilhot François,Nicolini Franck,Guilhot Joelle,Rousselot Philippe,Huguet Françoise,Legros Laurence,Gardembas Martine,Dubruille Viviane,Guerci-Bresler Agnès,Charbonnier Aude,Maloisel Frédéric,Ianotto Jean-Christophe,Villemagne Bruno,Mahon François-Xavier,Moins-Teisserenc Hélène,Dulphy Nicolas,Toubert Antoine

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects;Hematological Oncology;2024-09

2. A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment;Clinics and Practice;2024-06-21

3. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety;Expert Opinion on Drug Safety;2024-06-17

4. Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study;Frontiers in Oncology;2024-05-08

5. High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation;Cells;2024-04-22